Findings of a 7-year study revolutionized the standard protocol for patient management by reducing toxicities for patients with metastatic renal cell carcinoma (mRCC).
Sunitinib, an agent approved for use in several cancers, could prove useful in treatment of thymic carcinoma when traditional chemotherapy fails.
A trial comparing pazopanib and sunitinib found pazopanib to have better safety and health-related quality-of-life profiles among persons with metastatic renal cell carcinoma.
Markers in primary tumors such as CA9, CD31, CD34, and VEGFR1/2 might serve as predictors of a good response to sunitinib treatment in patients with metastatic clear cell renal carcinoma (ccRCC).
Animal studies have suggested that sunitinib may promote cancer growth and metastasis, but this does not appear to happen in humans.
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
Regorafenib, a new, targeted, oral drug, demonstrated the ability to control metastatic GIST, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies.
What is the role of sunitinib malate in the treatment of sarcomas?
Kidney cancer drugs in development could improve patients' quality of life and allow more effective treatment, according to Professor Robert Hawkins of Manchester University.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|